Effect of AF, olaparib and aurola treatment on immune-related

Frontiers The potential of PARP inhibitors in targeted cancer therapy and immunotherapy

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer

Evelien SMITS, Full Professor, PhD

Breast cancer heterogeneity and its implication in personalized precision therapy, Experimental Hematology & Oncology

Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells

An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic

Elly MARCQ, Postdoctoral Researcher, Doctor of Medicine

Christophe DEBEN, PostDoc Position, PhD

Antioxidants, Free Full-Text

Cancer Therapy Advisor March/April 2017 Issue by Haymarket Media - Issuu

PDF) Auranofin Synergizes with the PARP Inhibitor Olaparib to

PDF) Auranofin Synergizes with the PARP Inhibitor Olaparib to

Laurie FREIRE BOULLOSA, PhD Student